The Lund Report
Ken Hawkins, 77, may have received an experimental drug on Oct. 31, or a placebo. Either way, he's the first Oregon participant in a first-ever trial of a gene-editing infusion added to the bloodstream to stop the worsening of a potentially fatal heart condition.
About Us - The Lund Report
The Lund Report is an independent, nonpartisan, nonprofit, online news source. We exist to provide people in Oregon and southwest Washington with high-quality journalism about health care that promotes awareness and understanding of pressing issues while holding government and industry accountable.
Our mission - The Lund Report
The Lund Report is an independent, nonpartisan news service that exists to produce high-quality journalism about health care in Oregon and southwest Washington.Our public-service journalism promotes the awareness and understanding required for positive progress, while holding industry and government accountable. We bring to light the …
Our History - The Lund Report
Diane Lund-Muzikant founded The Lund Report in 2008 to provide watchdog journalism about a powerful but opaque industry: health care. She had no funding sources or investors, but she had plenty of tenacity and grit.“We won’t shy away from controversy or be intimidated by powerful special interest groups,” she wrote at the time. The Lund …
Latest News - The Lund Report
Ken Hawkins, 77, may have received an experimental drug on Oct. 31, or a placebo. Either way, he's the first Oregon participant in a first-ever trial of a gene-editing infusion added to the bloodstream to stop the worsening of a potentially fatal heart condition.
The Lund Report
A pile of flowers and a note eulogizing Bobby Smallwood, a security officer for Legacy Health, sit outside the Good Samaritan Medical Center, where he was killed during a confrontation on July 30, 2023.JAKE THOMAS/THE LUND REPORT
Jake Thomas - The Lund Report
Shelda Holmes in her office on Oct. 17, 2024, the day before she closed Hands On Medicine, the primary care clinic she founded in 2006. Even after closing the clinic, Holmes said she'll have years of work ahead of her to get paid for the care provided by the clinic.JAKE THOMAS/THE LUND REPORT
Hospitals - The Lund Report
Feb 2, 2023 · Ken Hawkins, 77, may have received an experimental drug on Oct. 31, or a placebo. Either way, he's the first Oregon participant in a first-ever trial of a gene-editing infusion added to the bloodstream to stop the worsening of a potentially fatal heart condition.
Newsletter - The Lund Report
Sign up for The Lund Report’s news alerts and get the latest health news headlines delivered to your inbox twice a week on Tuesdays and Thursdays.
Rural Health - The Lund Report
Sterling Hanakahi, 73, and Anita Hanakahi, 70, of Tillamook say they were blindsided when Texas-based U.S. Renal Care executives announced they would close their kidney dialysis center in the coastal community Feb. 23.